Emilio Emini Is The Key To Wyeth Vaccines
Executive Summary
In touting the $68 billion proposed deal for Wyeth, Pfizer CEO Jeff Kindler repeatedly cited Wyeth's vaccine business as a key part of the deal. But what exactly will Pfizer get after scooping up this unit? Two crucial assets - one is a product and the other is a person
You may also be interested in...
Pfizer’s New Org Chart Brings Eight Wyeth Execs Topside
In a move designed to allay concerns about post-Wyeth integration challenges, Pfizer outlined on April 7 the leadership structure of the future entity
Pfizer’s New Org Chart Brings Eight Wyeth Execs Topside
In a move designed to allay concerns about post-Wyeth integration challenges, Pfizer outlined on April 7 the leadership structure of the future entity
Pfizer Drafts A New “Org Chart” Post Wyeth Merger
Pfizer to appoint a number of key Wyeth execs to prominent positions post-merger, sending a clear signal that it is handling the integration of Wyeth differently from its previous acquisitions of Pharmacia and Warner Lambert.